Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
21 Nov, 2022 (Monday)

            
CHUNLI MEDICAL(1858)
Analysis:
Beijing Chunlizhengda Medical Instruments (1858) is mainly engaged in the manufacture and trading of surgical implants, instruments and related products. As of 30 June 2022, the Company held 59 medical device registration certificates and recordation certificates in the PRC for the production of medical devices which cover joint prosthesis products for the Company`s four major joints, spinal products and sports medical products. It is one of the domestic enterprises that hold the most comprehensive medical device registration certificates for joint prosthesis products in the PRC in terms of the numbers and types of certificates. Looking forward, various favourable factors such as aging population, continuous increase in per capita income and enlarging scope of the medical insurance coverage will continue to sustain the rapid development of the orthopedic medical device industry in the PRC. The Company will continue to diversify and expand the development of joint prosthesis products, knee joint prosthesis products, spinal products and sports medical products. (I do not hold the above stock)
Strategy:
Buy-in Price: $14.00, Target Price: $16.00, Cut Loss Price: $13.20


CR MEDICAL(1515)
Analysis:
China Resources Medical (01515) achieved a consolidated revenue of RMB2,850 million in the six months to the end of June 2022, an increase of 60.9% YoY; net profit attributable to shareholders was RMB202 million, an increase of 1.1% YoY. The results of the company recorded a stable growth and it was mainly attributable to the effective prevention and control of the COVID-19 epidemic in China, and also most of the member hospitals recorded a better year-on-year growth in their business volume, revenue and operating results during the Reporting Period that the overall number of out-patient visits and in-patient visits of our in-network hospitals were approximately 7,870,000 and 143,000, respectively and representing the respective year-on-year increase of 66.1% and 11.4%, and medical business revenue of our member hospitals recorded a year-on-year increase of 6.4%. During the period, China Resources Medical managed and operated a total of 120 medical institutions in 8 provinces and cities in the PRC. Seize the window period for the reform of state-owned hospitals and the corresponding merger and acquisition opportunities, it would expect the company would accelerate extensional growth.
Strategy:
Buy-in Price: $4.95, Target Price: $5.50, Cut Loss Price: $4.58



Wanfeng Auto Wheel (002085.CH) - Automobile Business Saw a Strong Rebound, Aircraft Business Saw Steady Growth with Sufficient Orders

Company Profile

After nearly 20 years of organic development and inorganic acquisitions, the Company has established a "dual engine" growth strategy driven by the application of lightweight metal materials in auto parts industry and the general aviation aircraft manufacturing industry, including six major business sectors, namely, 1) aluminum alloy wheels, 2), magnesium alloy automobile die castings, 3) high-strength steel stamping parts and other metal castings, 4) environmentally friendly dacromet coatings, and 5) general aviation aircraft. The Company is leading in many sub-industry fields.

Investment Summary

Cost Pressure Was Reduced and the Results Saw a Rebound from the Trough

Wanfeng Auto Wheels, based on the results report, recorded revenue of RMB11.7 billion in the first three quarters, up 37% yoy. The underlying reasons are the sufficient orders of the Company that kept mounting yoy, and the yoy increase in prices of main materials, as well as the optimization of the price and settlement mechanism. The net profit attributable to the parent company hit RMB590 million, up 152% yoy. The main reason is the improved profitability as yoy revenue growth outpaced cost increases, and the low base effect last year. In terms of profitability indicator, the gross margin and net profit margin in the first three quarters were 18.2% and 5.1%, up 2.2 and 2.3 ppts yoy, respectively. The return on net assets rose 5.6 ppts to 10.2% from a low of 4.6% last year. Additionally, the Company performed better than expected in controlling expenses. The period expense ratio dropped to a four-year low of 10.15%, down 2.21 ppts yoy..

Automobile Business Saw a Strong Rebound

With respect to business departments, the automobile metal parts lightweight business reported revenue of RMB10.215 billion, up 39.64% yoy. The profitability witnessed an overwhelming rebound, up 44.75% and 67.44% yoy in the automobile aluminium alloy wheel business and magnesium alloy die casting business, respectively.

Aided by the development dividend of the new-energy vehicle industry, the Company continued to consolidate the supply of magnesium alloy and aluminium alloy products in overseas OEMs. Meanwhile, the Company embarked on a broad path of the aluminium/magnesium alloy lightweight business in the new-energy vehicle industry chain and cooperated with mainstream new-energy vehicle companies such as BYD, Tesla, Rivian, NIO, Xiaopeng, Lixiang, Leapmotor, etc. While the Company's customer structure continued to be optimized, the products kept being innovative. With the rapid development of mainstream new energy car-making forces, the Company's supporting supply had also increased significantly. Sales volume of aluminium alloy wheels and magnesium alloy die-casting products for new-energy vehicles rocketed yoy. Furthermore, in the general trend of automobile lightweight, the amount of magnesium used in single vehicles gradually increased. The Company will continue to promote the construction of the Asia-pacific Centre for magnesium alloy business, thus further developing the business.

Aircraft Business Saw Steady Growth with Sufficient Orders

The general aviation aircraft manufacturing department, another major business, recorded revenue of RMB1.461 billion during the period, up 21.27% yoy with a steady business picture. The Company's general aviation aircraft manufacturing business is centred on innovative aircraft manufacturing, covering the business model of "R&D - authorisation/technology transfer - complete aircraft manufacturing and sales - after-sales service". During the reporting period, the general aviation aircraft manufacturing business had sufficient orders, and the sales business continued to be optimized. With the rising market share of Diamond Aircraft, the Company's after-sales service business had steadily improved. Meanwhile, the Company continuously developed and launched new high value-added models, such as the DA50, DA62 and the electric aircraft eDA40. As the general aviation market advances in the future, the Company's Diamond Aircraft will continue to develop new application scenarios on the basis of flight school training and other application markets. Through a wild range of aircraft models, domestic scenarios such as private flights, short-haul transportation, and specialized use will be further matched and developed. The domestic general aviation market, still in the early stage of development, enjoys a huge market..

Investment Thesis: Focus on the Follow-up Results Recovery

According to the latest financial data, we adjusted the EPS forecast for 2022 and 2023 to RMB 0.37/0.43, respectively (It was RMB0.29/0.43, respectively). We give the Company's target price to RMB 8.5, respectively 23/19.8/15 x P/E, 3.1/2.8/2.5 x P/B for 2022/2023/2024, a "BUY" rating. (Closing price as at 15 November)

Risk

Price war among peers

Raw material price increase

New business risk

Financials

Click Here for PDF format...




Recommendation on 21-11-2022
RecommendationBUY
Price on Recommendation Date$ 6.800
Suggested purchase priceN/A
Target Price$ 8.500
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2022 Phillip Securities (HK) Ltd. All Rights Reserved.